NCT01845805View on ClinicalTrials.gov

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 10, 2014

Primary Completion Date

April 9, 2021

Study Completion Date

April 9, 2021

Conditions
Pancreatic Cancer
Interventions
DRUG

oral azacitidine

OTHER

Observation

Trial Locations (4)

15212

Allegheny General Hospital, Pittsburgh

19104

The Hospital of the University of Pennsylvania, Philadelphia

21205

Johns Hopkins, Baltimore

21231

Sidney Kimmel Comprehensive Cancer Center, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01845805 - Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine) | Biotech Hunter | Biotech Hunter